Literature DB >> 23924849

Impact of adiponectin and leptin on long-term adverse events in Japanese patients with acute myocardial infarction. Results from the Nagoya Acute Myocardial Infarction Study (NAMIS).

Yasuhiro Morita1, Kengo Maeda, Takahisa Kondo, Hideki Ishii, Kyoko Matsudaira, Naoki Okumura, Hirotsugu Mitsuhashi, Rei Shibata, Toyoaki Murohara.   

Abstract

BACKGROUND: Low adiponectin levels and high leptin levels are associated with a high incidence of developing cardiovascular disease. However, the relationship between the levels of these adipokines and the development of adverse events after acute myocardial infarction (AMI) remains unclear. METHODS AND
RESULTS: This study enrolled 724 Japanese subjects with AMI who underwent successful emergency percutaneous coronary intervention (PCI). Their serum adiponectin and leptin levels were measured 7 days after AMI onset. There were 63 adverse events during the 3-year follow-up. The levels of adiponectin and leptin and the leptin to adiponectin ratio, were significantly associated with adverse events [hazard ratio 2.08 (95% confidence interval (CI) 1.33-3.24), P=0.001; hazard ratio 0.62 (95% CI 0.43-0.90), P=0.012; hazard ratio 0.59 (95% CI 0.45-0.76), P<0.001, respectively]. The leptin to adiponectin ratio remained a significant independent predictor of adverse events during long-term follow-up in a multivariable analysis [adjusted hazard ratio 0.60 (95% CI 0.43-0.83), P=0.002].
CONCLUSIONS: Higher adiponectin and lower leptin levels are associated with a high incidence of adverse events in Japanese patients after AMI, and the leptin to adiponectin ratio independently predicts prognosis after AMI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23924849     DOI: 10.1253/circj.cj-13-0251

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  9 in total

Review 1.  Adipose tissue and vascular inflammation in coronary artery disease.

Authors:  Enrica Golia; Giuseppe Limongelli; Francesco Natale; Fabio Fimiani; Valeria Maddaloni; Pina Elvira Russo; Lucia Riegler; Renatomaria Bianchi; Mario Crisci; Gaetano Di Palma; Paolo Golino; Maria Giovanna Russo; Raffaele Calabrò; Paolo Calabrò
Journal:  World J Cardiol       Date:  2014-07-26

Review 2.  Leptin, cardiovascular diseases and type 2 diabetes mellitus.

Authors:  Niki Katsiki; Dimitri P Mikhailidis; Maciej Banach
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

Review 3.  A Clinical Perspective: Contribution of Dysfunctional Perivascular Adipose Tissue (PVAT) to Cardiovascular Risk.

Authors:  Xiaoming Lian; Maik Gollasch
Journal:  Curr Hypertens Rep       Date:  2016-11       Impact factor: 5.369

4.  Cardiac rehabilitation may influence leptin and VEGF A crosstalk in patients after acute coronary syndrome.

Authors:  Damian Skrypnik; Katarzyna Skrypnik; Joanna Suliburska; Paweł Bogdański
Journal:  Sci Rep       Date:  2022-07-12       Impact factor: 4.996

5.  Association between hyperleptinemia and cardiovascular outcomes in patients with coronary artery disease.

Authors:  Ming-Chun Chen; Ji-Hung Wang; Chung-Jen Lee; Bang-Gee Hsu
Journal:  Ther Clin Risk Manag       Date:  2018-10-01       Impact factor: 2.423

6.  Correlation of Leptin With Acute Myocardial Infarction: A Case Control Study.

Authors:  Asghar Hussain Syed; Sameer Lohana; Norah H Aung; Muhammad Khizar Memon; Anam Shaikh; Sidra Memon; Syeda M Hassan; Besham Kumar
Journal:  Cureus       Date:  2020-12-20

7.  Smoking Functions as a Negative Regulator of IGF1 and Impairs Adipokine Network in Patients with Rheumatoid Arthritis.

Authors:  Malin C Erlandsson; Roberto Doria Medina; Sofia Töyrä Silfverswärd; Maria I Bokarewa
Journal:  Mediators Inflamm       Date:  2016-03-03       Impact factor: 4.711

8.  The role of selected adipokines and ghrelin in the prognosis after myocardial infarction in a 12-month follow-up in the presence of metabolic syndrome.

Authors:  Błażej Michalski; Ewa Szymczyk; Lukasz Peczek; Barbara Nawrot; Karolina Kupczynska; Maria Krzemińska-Pakuła; Jan Z Peruga; Piotr Lipiec; Jarosław D Kasprzak
Journal:  Arch Med Sci       Date:  2017-01-31       Impact factor: 3.318

9.  Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3.

Authors:  Simona Hogas; Stefana C Bilha; Dumitru Branisteanu; Mihai Hogas; Abduzhappar Gaipov; Mehmet Kanbay; Adrian Covic
Journal:  Arch Med Sci       Date:  2016-03-22       Impact factor: 3.318

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.